{"DataElement":{"publicId":"5863895","version":"1","preferredName":"Hematopoietic Cell Transplantation And/Or Cellular Therapy Primary Disease or Disorder Classification Type","preferredDefinition":"A description of the primary disease classification for which the hematopoietic cell transplantation and/or cellular therapy was performed.","longName":"5863894v1.0:2488348v2.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5863894","version":"1","preferredName":"Hematopoietic Cell Transplantation And/Or Cellular Therapy Primary Disease or Disorder Classification","preferredDefinition":"Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)_Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species._Used to indicate that either or both of two items or options may be valid._Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy._Occurring first in time or sequence; original; of greatest rank or importance or value._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"5863892v1.0:2321361v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5863892","version":"1","preferredName":"Hematopoietic Stem Cell Transplantation And/Or Cellular Therapy Primary Disease or Disorder","preferredDefinition":"Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.):Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.:Used to indicate that either or both of two items or options may be valid.:Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.:Occurring first in time or sequence; original; of greatest rank or importance or value.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"5863892v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Stem Cell","conceptCode":"C12551","definition":"Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C669AC-6C0D-3FBA-E053-F662850AD6FF","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-06-12","modifiedBy":"ONEDATA","dateModified":"2017-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C669AC-6C1B-3FBA-E053-F662850AD6FF","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-06-12","modifiedBy":"NYCHM","dateModified":"2017-08-31","changeDescription":"released 8/31/17mn.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2488348","version":"2.1","preferredName":"Primary Disease or Disorder Type","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Type; a subdivision of a particular kind of thing.","longName":"PRMRY_DS_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Severe aplastic anemia","valueDescription":"Severe aplastic anemia","ValueMeaning":{"publicId":"2580033","version":"1","preferredName":"Severe aplastic anemia","longName":"2580033","preferredDefinition":"Life-threatening anemia associated with a high risk of infection or bleeding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Severe Aplastic Anemia","conceptCode":"C61229","definition":"Life-threatening anemia associated with a high risk of infection or bleeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-05AE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-22","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-22","modifiedBy":"COOPERM","dateModified":"2019-11-14","changeDescription":"Added NCIt definition per NMDP request. mc 11/14/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AC51-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Histiocytic disorders","valueDescription":"Histiocytic disorders","ValueMeaning":{"publicId":"2580038","version":"1","preferredName":"Histiocytic disorders","longName":"2580038v1.00","preferredDefinition":"A group of non-neoplastic and neoplastic disorders characterized by the proliferation of histiocytes. This category includes hemophagocytic lymphohistiocytosis and histiocytic and dendritic cell neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic Disorder","conceptCode":"C203422","definition":"A group of non-neoplastic and neoplastic disorders characterized by the proliferation of histiocytes. This category includes hemophagocytic lymphohistiocytosis and histiocytic and dendritic cell neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-05B3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-22","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-22","modifiedBy":"KUMMEROA","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AC5B-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Immune deficiencies","valueDescription":"Immunodeficiency Syndrome","ValueMeaning":{"publicId":"2724511","version":"1","preferredName":"Immunodeficiency Syndrome","longName":"2724511","preferredDefinition":"A deficiency of immune response or a disorder characterized by deficient immune response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunodeficiency Syndrome","conceptCode":"C3131","definition":"Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4450987C-2254-3760-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AC65-5848-E040-BB89AD43651A","beginDate":"2008-01-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Inherited disorders of metabolism / osteopetrosis","valueDescription":"Congenital Metabolic Disorder Osteopetrosis","ValueMeaning":{"publicId":"2724512","version":"1","preferredName":"Congenital Metabolic Disorder Osteopetrosis","longName":"2724512","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.: Excessive formation of dense trabecular bone leading to pathological fractures, OSTEITIS, SPLENOMEGALY with infarct, ANEMIA, and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Osteopetrosis","conceptCode":"C26840","definition":"A rare genetic disorder inherited in an autosomal dominant, autosomal recessive, or X-linked recessive pattern. In the majority of cases it is caused by mutations in the CLCN7, TCIRG1, or IKBKG genes. It is characterized by excessive bone formation due to the failure of osteoclasts to resorb bone. It manifests with deformities, fractures, hepatosplenomegaly, anemia, and extramedullary hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4450987C-227C-3760-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AC6F-5848-E040-BB89AD43651A","beginDate":"2008-01-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Platelet disorder","valueDescription":"Platelet Diseases and Disorders","ValueMeaning":{"publicId":"2724513","version":"1","preferredName":"Platelet Diseases and Disorders","longName":"2724513","preferredDefinition":"platelet. An irregularly shaped disklike cytoplasmic fragment of a megakaryocyte that is shed in the marrow sinus and subsequently found in the peripheral blood where it functions in clotting. A platelet contains granules in the central part (granulomere) and, peripherally, clear protoplasm (hyalomere), but no definite nucleus; is about one-third to one-half the size of an erythrocyte; and contains no hemoglobin. (STED98): A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Platelet","conceptCode":"C12520","definition":"An irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4450987C-22A1-3760-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AC79-5848-E040-BB89AD43651A","beginDate":"2008-01-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Anemia / hemoglobinopathy","valueDescription":"Anemia Hemoglobinopathy","ValueMeaning":{"publicId":"2724514","version":"1","preferredName":"Anemia Hemoglobinopathy","longName":"2724514","preferredDefinition":"A reduction in the number of red blood cells per cu mm, the amount of hemoglobin in 100 ml of blood, and the volume of packed red blood cells per 100 ml of blood. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. --2004: A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anemia","conceptCode":"C2869","definition":"A reduction in the number of red blood cells, the amount of hemoglobin, and/or the volume of packed red blood cells. Clinically, anemia represents a reduction in the oxygen-transporting capacity of a designated volume of blood, resulting from an imbalance between blood loss (through hemorrhage or hemolysis) and blood production. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hemoglobinopathy","conceptCode":"C3092","definition":"An inherited disorder characterized by structural alterations of a globin chain within the hemoglobin molecule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4450987C-22C9-3760-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AC83-5848-E040-BB89AD43651A","beginDate":"2008-01-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Other malignancies","valueDescription":"Other Malignant Neoplasm","ValueMeaning":{"publicId":"2683293","version":"1","preferredName":"Other Malignant Neoplasm","longName":"2683293","preferredDefinition":"Not otherwise specified.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A947A96-C0C6-73DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-20","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AC8D-5848-E040-BB89AD43651A","beginDate":"2008-01-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Autoimmune diseases","valueDescription":"Autoimmune Disease","ValueMeaning":{"publicId":"2585785","version":"1","preferredName":"Autoimmune Disease","longName":"2585785","preferredDefinition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis). \r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Disease","conceptCode":"C2889","definition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26B7A966-8345-0BC2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-01-10","modifiedBy":"TAYLORT","dateModified":"2020-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AE25-5848-E040-BB89AD43651A","beginDate":"2008-01-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Acute lymphoblastic leukemia (ALL)","valueDescription":"ALL","ValueMeaning":{"publicId":"2573071","version":"1","preferredName":"ALL","longName":"2573071","preferredDefinition":"A leukemia with an acute onset, characterized by the presence of lymphoblasts or Burkitt cells in the bone marrow and the peripheral blood.  It includes the precursor B lymphoblastic leukemia, precursor T lymphoblastic leukemia, and Burkitt's leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"KUMMEROA","dateModified":"2022-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-ACA1-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Acute myelogenous leukemia (AML or ANLL)","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-ACAB-5848-E040-BB89AD43651A","beginDate":"2006-11-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Breast cancer","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"2581276","version":"1","preferredName":"Breast Carcinoma","longName":"2581276","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AE2F-5848-E040-BB89AD43651A","beginDate":"2008-01-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Chronic myelogenous leukemia (CML)","valueDescription":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","ValueMeaning":{"publicId":"2558495","version":"1","preferredName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive","longName":"2558495","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B18C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-ACBF-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Inherited abnormalities of erythrocyte differentiation or function","valueDescription":"Congenital Abnormalities of Erythrocyte Differentiation or Function","ValueMeaning":{"publicId":"2593283","version":"1","preferredName":"Congenital Abnormalities of Erythrocyte Differentiation or Function","longName":"2593283","preferredDefinition":"Inherited disorders involving abnormalities of red blood cell function, structure, or production. Some diseases in this group may be associated with bone marrow failure, neutropenia, and/or thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Abnormalities of Erythrocyte Differentiation or Function","conceptCode":"C61234","definition":"Inherited disorders involving abnormalities of red blood cell function, structure, or production. Some diseases in this group may be associated with bone marrow failure, neutropenia, and/or thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28821787-398D-1913-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"COOPERM","dateModified":"2019-11-14","changeDescription":"Added NCIt definition per NMDP request. mc 11/14/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-ACC9-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Inherited disorders of metabolism","valueDescription":"Congenital Metabolic Disorder","ValueMeaning":{"publicId":"2593446","version":"1","preferredName":"Congenital Metabolic Disorder","longName":"2593446","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAAEC-6B31-4B12-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-ACD3-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Multiple myeloma / plasma cell disorder (PCD)","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"2559811","version":"1","preferredName":"Plasma Cell Myeloma","longName":"2559811","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-ACDD-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Disorders of the immune system","valueDescription":"Immune System Disorder","ValueMeaning":{"publicId":"2578546","version":"1","preferredName":"Immune System Disorder","longName":"2578546","preferredDefinition":"A disorder resulting from an abnormality in the immune system. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune System Disorder","conceptCode":"C3507","definition":"A disorder resulting from an abnormality in the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFDF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-05","modifiedBy":"ONEDATA","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AE11-5848-E040-BB89AD43651A","beginDate":"2013-05-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Non-Hodgkin lymphoma","valueDescription":"Non-Hodgkin lymphoma","ValueMeaning":{"publicId":"2568326","version":"1","preferredName":"Non-Hodgkin lymphoma","longName":"2568326","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, Non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-02","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-ACF1-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Hodgkin lymphoma","valueDescription":"Hodgkin's Lymphoma","ValueMeaning":{"publicId":"2581278","version":"1","preferredName":"Hodgkin's Lymphoma","longName":"2581278","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells.  There are two distinct subtypes: nodular lymphocyte predominant Hodgkin's lymphoma and classical Hodgkin's lymphoma.  Hodgkin's lymphoma has a bimodal age distribution, and involves primarily lymph nodes.  Current therapy for Hodgkin's lymphoma has resulted in an excellent outcome and cure for the majority of patients. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"LEATHERJ","dateModified":"2008-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-ACFB-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Other acute leukemia","valueDescription":"Other Acute Leukemia","ValueMeaning":{"publicId":"2725264","version":"1","preferredName":"Other Acute Leukemia","longName":"2725264","preferredDefinition":"Not otherwise specified.: leukemia in which the involved cell shows little or no differentiation, usually consisting of blast cells; two types are distinguished, acute lymphocytic and acute myelogenous leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44CDEB64-65AB-3A82-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AD05-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Other disease","valueDescription":"Other Diseases and Disorders","ValueMeaning":{"publicId":"2725265","version":"1","preferredName":"Other Diseases and Disorders","longName":"2725265","preferredDefinition":"Not otherwise specified.: A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44CDEB64-65D0-3A82-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AD0F-5848-E040-BB89AD43651A","beginDate":"2006-11-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Solid tumors","valueDescription":"Solid Neoplasm","ValueMeaning":{"publicId":"2593121","version":"1","preferredName":"Solid Neoplasm","longName":"2593121","preferredDefinition":"Cancer of body tissues other than blood, bone marrow, or the lymphatic system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D4DB6-4D12-242A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AD19-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AD2D-5848-E040-BB89AD43651A","beginDate":"2009-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Inherited abnormalities of platelets","valueDescription":"Congenital Platelets Abnormality","ValueMeaning":{"publicId":"3115733","version":"1","preferredName":"Congenital Platelets Abnormality","longName":"3115733","preferredDefinition":"A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Platelets Abnormality","conceptCode":"C61247","definition":"A group of rare inherited platelet disorders that involve abnormalities of platelet function or platelet production and that usually cause moderate to severe bleeding problems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A436A18-387F-2C9C-E040-BB89AD43650B","latestVersionIndicator":"Yes","beginDate":"2010-06-30","endDate":null,"createdBy":"WHITES","dateCreated":"2010-06-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AD37-5848-E040-BB89AD43651A","beginDate":"2010-06-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Other leukemia","valueDescription":"Other Leukemia","ValueMeaning":{"publicId":"2683292","version":"1","preferredName":"Other Leukemia","longName":"2683292","preferredDefinition":"Not otherwise specified.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A947A96-C0A1-73DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-20","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AE57-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Myelodysplastic (MDS) / myeloproliferative (MPN) diseases","valueDescription":"Myelodysplastic/Myeloproliferative Disease","ValueMeaning":{"publicId":"2590868","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Disease","longName":"2590868","preferredDefinition":"A category of clonal myeloid disorders that have both myelodysplastic and chronic myeloproliferative features at the time of initial presentation.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm","conceptCode":"C27262","definition":"A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"284500E6-BC71-45B5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE03E4BC-AE82-5848-E040-BB89AD43651A","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"ONEDATA","dateModified":"2013-05-31","deletedIndicator":"No"},{"value":"Acute leukemia of ambiguous lineage and other myeloid neoplasms","valueDescription":"Acute Leukemia of Ambiguous Lineage And Other Myeloid Neoplasm","ValueMeaning":{"publicId":"5564775","version":"1","preferredName":"Acute Leukemia of Ambiguous Lineage And Other Myeloid Neoplasm","longName":"5564775","preferredDefinition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Different than the one(s) previously specified or mentioned.: Diseases in which too many blood cells are made in the bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia of Ambiguous Lineage","conceptCode":"C7464","definition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Myeloid Neoplasm","conceptCode":"C9290","definition":"Proliferation of myeloid cells originating from a primitive stem cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"406A4DBB-A3A3-2DEC-E053-F662850ACB9A","latestVersionIndicator":"Yes","beginDate":"2016-11-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"406B5830-272B-28DC-E053-F662850AFE4F","beginDate":"2016-11-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-03","modifiedBy":"ONEDATA","dateModified":"2016-11-03","deletedIndicator":"No"},{"value":"Recessive dystrophic epidermolysis bullosa","valueDescription":"Epidermolysis Bullosa Dystrophica, Autosomal Recessive","ValueMeaning":{"publicId":"6568819","version":"1","preferredName":"Epidermolysis Bullosa Dystrophica, Autosomal Recessive","longName":"6568819","preferredDefinition":"An autosomal recessive allelic variant of epidermolysis bullosa dystrophica caused by mutation(s) in the COL7A1 gene, encoding collagen alpha-1(VII) chain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epidermolysis Bullosa Dystrophica, Autosomal Recessive","conceptCode":"C156446","definition":"An autosomal recessive allelic variant of epidermolysis bullosa dystrophica caused by mutation(s) in the COL7A1 gene, encoding collagen alpha-1(VII) chain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BA95203-0BDE-2942-E053-F662850A5CF0","latestVersionIndicator":"Yes","beginDate":"2018-11-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C4C259F-FD39-48C8-E053-F662850A9E07","beginDate":"2018-11-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-05","modifiedBy":"ONEDATA","dateModified":"2018-12-05","deletedIndicator":"No"},{"value":"Tolerance induction associated with solid organ transplant","valueDescription":"Tolerance Induction in Solid Organ Transplantation","ValueMeaning":{"publicId":"6568820","version":"1","preferredName":"Tolerance Induction in Solid Organ Transplantation","longName":"6568820","preferredDefinition":"An immunological environment, mediated by T-regulatory cells, favoring regulation, supporting graft survival, without interfering with crucial immune surveillance mechanisms and, concurrently, abolishing immunosuppressant-related toxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tolerance Induction in Solid Organ Transplantation","conceptCode":"C156451","definition":"An immunological environment, mediated by T-regulatory cells, favoring regulation, supporting graft survival, without interfering with crucial immune surveillance mechanisms and, concurrently, abolishing immunosuppressant-related toxicity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BA95203-0C03-2942-E053-F662850A5CF0","latestVersionIndicator":"Yes","beginDate":"2018-11-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-11-27","modifiedBy":"KUMMEROA","dateModified":"2020-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BA95203-0C1C-2942-E053-F662850A5CF0","beginDate":"2018-11-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-11-27","modifiedBy":"ONEDATA","dateModified":"2018-11-27","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome (MDS)","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"3946618","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"3946618","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA87B0E5-6712-6876-E040-BB89AD437204","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-06","modifiedBy":"GDEEN","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"851377A7-AEEE-7055-E053-F662850A787A","beginDate":"2019-03-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-03-27","modifiedBy":"ONEDATA","dateModified":"2019-03-27","deletedIndicator":"No"},{"value":"Myeloproliferative neoplasms (MPN)","valueDescription":"Myeloproliferative Neoplasm","ValueMeaning":{"publicId":"4264963","version":"1","preferredName":"Myeloproliferative Neoplasm","longName":"4264963","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3B48-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DFEBE69-7759-26FC-E053-F662850A018E","beginDate":"2020-02-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-07","modifiedBy":"ONEDATA","dateModified":"2020-02-07","deletedIndicator":"No"},{"value":"Paroxysmal nocturnal hemoglobinuria (PNH)","valueDescription":"Paroxysmal Nocturnal Hemoglobinuria","ValueMeaning":{"publicId":"2593267","version":"1","preferredName":"Paroxysmal Nocturnal Hemoglobinuria","longName":"2593267","preferredDefinition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paroxysmal Nocturnal Hemoglobinuria","conceptCode":"C61233","definition":"A rare acquired hematologic disorder characterized by hemolytic anemia, dark-colored urine due to the release of hemoglobin in the blood, and thrombosis. The episodes of hemolysis tend to occur at night. It is caused by a somatic mutation in the glycosylphosphatidylinositol biosynthesis gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2880CCB0-13F1-07E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AAE33E4A-3525-3C25-E053-4EBD850A3BE5","beginDate":"2020-07-20","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-20","modifiedBy":"ONEDATA","dateModified":"2020-07-20","deletedIndicator":"No"},{"value":"Hemoglobinopathies","valueDescription":"Hemoglobinopathy","ValueMeaning":{"publicId":"2593295","version":"1","preferredName":"Hemoglobinopathy","longName":"2593295","preferredDefinition":"A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemoglobinopathy","conceptCode":"C3092","definition":"An inherited disorder characterized by structural alterations of a globin chain within the hemoglobin molecule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28821A9F-371A-19B1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AAE33E4A-3539-3C25-E053-4EBD850A3BE5","beginDate":"2020-07-20","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-20","modifiedBy":"ONEDATA","dateModified":"2020-07-20","deletedIndicator":"No"},{"value":"Inherited bone marrow failure syndromes","valueDescription":"Inherited Bone Marrow Failure Syndrome","ValueMeaning":{"publicId":"7359840","version":"1","preferredName":"Inherited Bone Marrow Failure Syndrome","longName":"7359840","preferredDefinition":"A group of inherited genetic hematopoietic stem cell disorders characterized by bone marrow failure that involves one or more cell lines. Representative examples include Fanconi anemia, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inherited Bone Marrow Failure Syndrome","conceptCode":"C94810","definition":"A group of inherited genetic hematopoietic stem cell disorders characterized by bone marrow failure that involves one or more cell lines. Representative examples include Fanconi anemia, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAE33E4A-3543-3C25-E053-4EBD850A3BE5","latestVersionIndicator":"Yes","beginDate":"2020-07-20","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-20","modifiedBy":"ONEDATA","dateModified":"2020-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AAE33E4A-355C-3C25-E053-4EBD850A3BE5","beginDate":"2020-07-20","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-20","modifiedBy":"ONEDATA","dateModified":"2020-07-20","deletedIndicator":"No"},{"value":"Aplastic Anemia","valueDescription":"Aplastic Anemia","ValueMeaning":{"publicId":"2593270","version":"1","preferredName":"Aplastic Anemia","longName":"2593270","preferredDefinition":"A condition in which the bone marrow is unable to produce blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aplastic Anemia","conceptCode":"C2870","definition":"Anemia resulting from bone marrow failure (aplastic or hypoplastic bone marrow). The production of erythroblasts and red cells is markedly decreased, and it may be associated with decreased production of granulocytes (granulocytopenia) and platelets (thrombocytopenia) as well. Aplastic anemia may be idiopathic or secondary due to bone marrow damage by toxins, radiation, or immunologic factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2880D74E-659D-0A0D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AAE33E4A-3566-3C25-E053-4EBD850A3BE5","beginDate":"2020-07-20","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-07-20","modifiedBy":"ONEDATA","dateModified":"2020-07-20","deletedIndicator":"No"},{"value":"Mixed phenotype acute leukemia (MPAL)","valueDescription":null,"ValueMeaning":{"publicId":"7000422","version":"1","preferredName":"Mixed Phenotype Acute Leukemia","longName":"7000422","preferredDefinition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia","conceptCode":"C82179","definition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"950E57BC-8DF0-20B0-E053-F662850A4478","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-10-16","modifiedBy":"KUMMEROA","dateModified":"2023-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07852A52-AA58-5C66-E063-731AD00A5BD4","beginDate":"2023-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-10-12","modifiedBy":"KUMMEROA","dateModified":"2023-10-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008584","version":"1","preferredName":"Disease-Disorder Classification","preferredDefinition":"the grouping of diseases and disorders into classes or categories.","longName":"DZ_DISORDER_CLASS","context":"EDRN","contextVersion":"1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"CAAB9A16-A8FF-455E-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-10-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2003-10-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2724510","version":"1","preferredName":"Primary Diseases and Disorders Type","preferredDefinition":"Occurring first in time or sequence; original. (American Heritage Dictionary):A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.:Type; a subdivision of a particular kind of thing.","longName":"C25251:C2991:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44509874-FEA5-375E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-22","modifiedBy":"ONEDATA","dateModified":"2008-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE03E4BC-AC3B-5848-E040-BB89AD43651A","latestVersionIndicator":"Yes","beginDate":"2006-06-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-05-31","modifiedBy":"KUMMEROA","dateModified":"2023-10-12","changeDescription":". PV added for 2402. AK 11/3/16 Added 2 new PVs for 2402r4. AK 11/27/18. Added PVs for 2402r6. 07/20/2020 KMM Corrected PV def for KM. AK 2020-10-19","administrativeNotes":"2023.10.12 PV added per ticket request CADSR0002943. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TDIS_PDH_hct_prime_dis_class","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_PDH_hct_ct_prim_dis_clas","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the primary disease","type":"Preferred Question Text","description":"What was the primary disease for which the hematopoietic cell transplantation and/or cellular therapy was performed?","url":null,"context":"NHLBI"},{"name":"What was the primary disease for which the HCT / cellular therapy was performed?","type":"Alternate Question Text","description":"What was the primary disease for which the HCT / cellular therapy was performed?","url":null,"context":"NHLBI"},{"name":"What was the primary disease for which the HCT / cellular therapy was performed?","type":"Application Standard Question Text","description":"What was the primary disease for which the HCT / cellular therapy was performed?","url":null,"context":"NHLBI"},{"name":"What is the primary disease for which the HCT / cellular therapy is being performed?","type":"Alternate Question Text","description":"What is the primary disease for which the HCT / cellular therapy is being performed?","url":null,"context":"NHLBI"},{"name":"What is the primary disease for which the HCT is being performed?","type":"Alternate Question Text","description":"What is the primary disease for which the HCT is being performed?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"51C6422B-D94D-2616-E053-F662850A449B","latestVersionIndicator":"Yes","beginDate":"2017-06-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-06-12","modifiedBy":"KUMMEROA","dateModified":"2019-11-15","changeDescription":"System generated def displayed as alt def. released 8/31/17mn. Added AQT. 04/05/2019 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}